Damora Therapeutics Inc - Company Profile
Powered by 
All the sales intelligence you need on Damora Therapeutics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Damora Therapeutics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Damora Therapeutics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Damora Therapeutics Inc (Damora Therapeutics), formerly Galecto Inc, is a biotechnology company. The company advances subcutaneous treatments specifically designed to provide the first targeted, disease-modifying options for patients living with mutant calreticulin-driven myeloproliferative neoplasms. Its pipeline products include DMR-001, which treats essential thrombocythemia and myelofibrosis; DMR-002, for mutant calreticulin-driven myeloproliferative neoplasms; DMR-003, which targets mutant calreticulin-driven myeloproliferative neoplasms; and GB3226, for ENL-YEATS and FLT3-driven disorders. Damora Therapeutics is headquartered in Waltham, Massachusetts, the US
Headquarters
United States of America
Address
Building 23, Suite 105, 221 Crescent Street, Waltham, Massachusetts, 02453
Website
damoratx.com
Telephone
1 781 2819020
No of Employees
7
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
DMRA (NASD)
EPS
XYZ
Net Income (2024)
XYZ
-878.8%
(2024 vs 2023)
Market Cap*
$1.7B
* As of and is in US$
Damora Therapeutics Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| GB3226: ENL-YEATS and FLT3 |
| DMR-001: Mutant calreticulin (mutCALR)-driven Myeloproliferative Neoplasms (MPNs) |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Acquisitions/Mergers/Takeovers | In November, the company completed the acquisition of Damora Therapeutics Inc, a biotechnology company. |
| 2024 | Acquisitions/Mergers/Takeovers | In October, the company acquired the global rights to BRM-1420 from Bridge Medicines. |
| 2024 | Others | In October, the company announced an intensive strategic review process and determined to focus on cancer and liver disease, leveraging its existing clinical stage asset GB1211. |
Competitor Comparison
| Key Parameters | Damora Therapeutics Inc | AbbVie Inc | Novartis AG | Bristol-Myers Squibb Co | Boehringer Ingelheim International GmbH |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Switzerland | United States of America | Germany |
| City | Waltham | North Chicago | Basel | Princeton | Ingelheim am Rhein |
| State/Province | Massachusetts | Illinois | Basel-Stadt | New Jersey | Rheinland-Pfalz |
| No. of Employees | 7 | 57,000 | 75,267 | 32,500 | 54,300 |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Peter Harwin | Chairman | Executive Board | 2025 | 40 |
| Jennifer Jarrett | Chief Executive Officer; Director; President | Executive Board | 2026 | 55 |
| Lori Firmani | Chief Financial Officer | Senior Management | 2024 | 53 |
| Sherwin Sattarzadeh | Chief Operating Officer | Senior Management | 2026 | 47 |
| Becker Hewes | Chief Medical Officer | Senior Management | 2026 | 60 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer